The studies — led by Professor Uri Ben-David and doctoral student Johanna Zerbib in Tel Aviv, and Professor Stefano Santaguida and doctoral student Marica Rosaria Ippolito in Milan — discovered two main weaknesses in aneupoloid cells.

What makes this treatment particularly remarkable is its effectiveness—early results indicate that over 80% of patients have experienced significant relief.

Further research is needed to determine if manipulating the gut microbiome could be a viable treatment approach for ASD.

The new treatment works on patients who already have the coronavirus and is being fast-tracked for patenting and production.